PARP inhibitors in prostate cancers, is it time for combinations?
Diego TeyssonneauCharles DarianeEric BarretJean-Baptiste BeauvalLaurent BrureauGaëlle FiardGaëlle FromontGilles CréhangeMathieu GauthéAlain RuffionRaphaële Renard-PennaRomain MathieuPaul SargosMorgan RouprêtGuillaume PloussardGuilhem RoubaudPublished in: Therapeutic advances in medical oncology (2024)
Despite several improvements in outcomes, metastatic prostate cancer remains deadly. Alterations in the homologous recombination repair (HRR) pathway are associated with more aggressive disease. Olaparib and rucaparib, two poly-ADP-ribose polymerase (PARP) inhibitors, have received approval from the authorities of several countries for their anti-tumoral effects in patients with metastatic castration-resistant prostate cancers harboring HRR gene alterations, in particular BRCA2 . More recently, it has been hypothesized that new hormonal therapies (NHTs) and PARP inhibitors (PARPi) could have synergistic actions and act independently of HRR deficiency. This review proposes to discuss the advantages and disadvantages of PARPi used as monotherapy or in combination with NHTs and whether there is a need for molecular selection.
Keyphrases
- prostate cancer
- dna repair
- dna damage
- radical prostatectomy
- squamous cell carcinoma
- small cell lung cancer
- benign prostatic hyperplasia
- oxidative stress
- randomized controlled trial
- type diabetes
- genome wide
- copy number
- gene expression
- cancer therapy
- metabolic syndrome
- open label
- drug delivery
- young adults
- double blind